Clinical Trials Logo

Labyrinth Diseases clinical trials

View clinical trials related to Labyrinth Diseases.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01526174 Terminated - Clinical trials for Autoimmune Inner Ear Disease

Intratympanic Injection for Autoimmune Inner Ear Disease

AIED
Start date: March 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The investigators plan to conduct an open-label intratympanic injection proof-of-concept trial of golimumab, a TNF-alpha inhibitor, assessing for hearing loss progression in patients with autoimmune inner ear disease (AIED). This specific aim will be achieved using a two-arm approach. First, the investigators propose to dose 3 individual subjects with a single intratympanic injection of golimumab and follow each for 30 days, closely examining them for adverse events. If there are no serious adverse events, with FDA approval, the investigators propose to dose 14 subjects, each with 4 intratympanic injections of golimumab.